Meeting Wed, 01/15/2025 - 12:00 Drug Utilization Review Board Meeting Information

Date
Media
Pharmacy January 2025
Edit Implementation Schedule for January 2025
PDL Recommendations January 2025
PDL Announcements January 2025
Relias BPM January 2025
Conduent Reports January 2025
New Drugs January 2025
Conduent RDUR Report Presentation January 2025
Agenda
DUR Agenda January 2025
Minutes
DUR Minutes January 2025 Draft
Criteria
DUR Criteria
Clinical and Fiscal Edits- Existing Criteria
Media
Antipsychotics - 1st Generation (Typical) January 2025
Benzodiazepine (Select Oral) January 2025
Butalbital Combinations without Codeine January 2025
Camzyos January 2025
Corlanor January 2025
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators January 2025
HBV Nucleotide Analog Reverse Transcriptase Inhibitors January 2025
High Risk Therapies January 2025
Morphine Milligram Equivalent Accumulation January 2025
Selzentry January 2025
Sohonos January 2025
Verquvo January 2025
Ztalmy January 2025
DUR Criteria
Clinical and Fiscal Edits- New or Revised of Existing Criteria
Media
Anti-Amyloid Monoclonal Antibody January 2025
Botulinum Toxin January 2025
Duchenne Muscular Dystrophy January 2025
Enzyme Deficiency Select Agents January 2025
Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) Stabilizers January 2025
Lenmeldy January 2025
Opioids, Short-Acting January 2025
Prior Authorization Required Fiscal Edit January 2025
Skysona January 2025
DUR Criteria
Resource List - New or Revised Criteria
Media
Antipsychotics - 2nd Generation (Atypical) Depot Agents Resource List January 2025
Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents Resource List January 2025
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Alzheimer’s Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists & Combinations January 2025
Antibiotics, Gastrointestinal (GI) January 2025
Antibiotics, Mupirocin Topical January 2025
Anti-Migraine, Serotonin (5-HT1) Receptor Agonists January 2025
Anti-Parkinsonism, MAO-B Inhibitors January 2025
Anti-Parkinsonism, Non-Ergot Dopamine Agonists January 2025
Fibromyalgia Agents January 2025
Glucagon Agents January 2025
Hereditary Angioedema Agents January 2025
Opioids, Long Acting January 2025
Sedative Hypnotics January 2025
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Antibiotics, Vaginal January 2025
Anticonvulsants, Dravet Syndrome January 2025
Antiemetics, 5-HT3 and NK1 Injectables January 2025
Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables January 2025
Anti-Migraine, Alternative Agents January 2025
Antiretroviral Therapy (ART) January 2025
Calcitonin Gene-Related Peptide (CGRP) Inhibitors January 2025
Cephalosporin Agents January 2025
Fluoroquinolones, Oral January 2025
Gene Therapies for Sickle Cell Disease and Beta-Thalassemia January 2025
GI Motility Agents, Chronic January 2025
Macrolides January 2025
Neuropathic Pain Agents January 2025
NSAIDs January 2025
Opioid & Select Alcohol Dependence Agents January 2025
Opioid Emergency Reversal Agents January 2025
Penicillin Agents January 2025
Skeletal Muscle Relaxants January 2025
Somatostatin Analogs January 2025
Tetracyclines January 2025
Tramadol-Like Agents January 2025
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors January 2025
Page
Drug Utilization Review Board Meeting Information